Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Q2 2021 vs. Q1 2021
How the institutions holding Immunovant, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 120 | 110 | −10 |
| Shares | 40.4M | 38.6M | −1.89M (−4.7%) |
| Value | $654.3M | $407.5M | −$246.8M (−37.7%) |
New holders (21)
Institutions that held Immunovant, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (31)
Institutions that held Immunovant, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.